Aristopharma Ltd

Our Products

Atanib (Afatinib)

Therapeutic Group : Tyrosine Kinase Inhibitor (Oncology)

Share on facebook
Share on twitter
Share on print
Share on email
Afatinib demonstrated inhibition of auto phosphorylation and/or in vitro proliferation of cell lines expressing wild-type EGFR and in those expressing selected EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common non-resistant mutations, at Afatinib concentrations achieved in patients. In addition, Afatinib inhibits in vitro proliferation of cell lines over expressing HER2.